Literature DB >> 22741941

Effective treatment of Kaposi's sarcoma by electrochemotherapy and intravenous bleomycin administration.

A Latini1, A Bonadies, E Trento, S Bultrini, C Cota, F M Solivetti, C Ferraro, M Ardigò, B Amorosi, G Palamara, S Bucher, M Giuliani, P Cordiali-Fei, F Ensoli, A Di Carlo.   

Abstract

The present prospective study was aimed at evaluating the long-term efficacy of local electrochemotherapy (ECT) with the intravenous administration of bleomycin, on disease progression and viral activity in classic Kaposi's sarcoma (cKS), a vascular tumor related to human herpes virus-8 infection. Eighteen patients affected by isolate or multiple cutaneous lesions, refractory to conventional treatments, although in the absence of visceral involvement, were enrolled in a study. Follow-up visits were performed after 4 weeks and every 6 months for up to 48 months. A more extensive exploration of the immunologic status as well as of virological parameters was performed in nine patients. The results showed a significant clinical improvement in all patients after 4 weeks. A complete regression was observed in 12 patients after the first ECT, while four patients required a second treatment on the residual lesions after 4 weeks from the first intervention. The positive outcome persisted during the subsequent clinical control visits. Two patients, that showed rapidly evolving did not improve and relapsed despite a second round of ECT treatment. Effective treatment was associated with the reduction of viral load to undetectable levels. These data support the conduct of larger studies directed at validating the efficacy of ECT as a first-line therapy for cKS.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22741941     DOI: 10.1111/j.1529-8019.2012.01437.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  5 in total

1.  Electrochemotherapy treatment of locally advanced and metastatic soft tissue sarcomas: results of a non-comparative phase II study.

Authors:  Luca G Campana; Giuseppe Bianchi; Simone Mocellin; Sara Valpione; Laura Campanacci; Antonella Brunello; Davide Donati; Elisabetta Sieni; Carlo R Rossi
Journal:  World J Surg       Date:  2014-04       Impact factor: 3.352

2.  Kaposi's Sarcoma-Associated Herpesvirus Utilizes and Manipulates RNA N6-Adenosine Methylation To Promote Lytic Replication.

Authors:  Fengchun Ye; E Ricky Chen; Timothy W Nilsen
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

3.  Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience.

Authors:  Manuela Colafigli; Arturo Ciccullo; Alberto Borghetti; Iuri Fanti; Federico Melis; Sara Modica; Ilaria Uccella; Antonio Bonadies; Virginia Ferraresi; Enza Anzalone; Alfredo Pennica; Emilia Migliano; Barbara Rossetti; Giordano Madeddu; Roberto Cauda; Antonio Cristaudo; Simona Di Giambenedetto; Alessandra Latini
Journal:  J Clin Med       Date:  2019-11-23       Impact factor: 4.241

Review 4.  Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review.

Authors:  Luca G Campana; A James P Clover; Sara Valpione; Pietro Quaglino; Julie Gehl; Christian Kunte; Marko Snoj; Maja Cemazar; Carlo R Rossi; Damijan Miklavcic; Gregor Sersa
Journal:  Radiol Oncol       Date:  2016-02-16       Impact factor: 2.991

Review 5.  Activation of DNA Damage Response Induced by the Kaposi's Sarcoma-Associated Herpes Virus.

Authors:  Enea Gino Di Domenico; Luigi Toma; Valentina Bordignon; Elisabetta Trento; Giovanna D'Agosto; Paola Cordiali-Fei; Fabrizio Ensoli
Journal:  Int J Mol Sci       Date:  2016-06-01       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.